|
|
|
| Effects of Neoadjuvant Chemotherapy with Paclitaxel and Cisplatin on Lymph Node Metastasis and Long Term of Prognosis in Patients with Advanced Cervical Cancer |
| XIANG Anling, ZHUANG Ruichun, PENG Ling |
| Chongqing Kaizhou District People's Hospital, Chongqing 400000, China |
|
|
|
|
Abstract Objective: To analyze the effects of neoadjuvant chemotherapy with paclitaxel and cisplatin on lymph node metastasis and long term of prognosis in patients with advanced cervical cancer. Methods: 78 cases of advanced cervical cancer who underwent radical hysterectomy and pelvic lymph node dissection were selected in our hospital and were randomly divided into the control group and study group, with 39 cases in each group. The control group underwent the treatment program of cisplatin, leucovorin calcium, fluorouracil glucoside and doxorubicin before surgery, and the study group were treated with neoadjuvant chemotherapy with paclitaxel and cisplatin before surgery. The rate of lymph node metastasis and long term of prognosis were compared between the two groups after treatment. Results:The total efficiency of the study group was higher than that of the control group (P<0.05); the rate of lymph node metastasis, vascular invasion, parametrial involvement in the study group were lower than those in the control group (P<0.05); the incidence rate of adverse reactions of the two groups showed no different significance (P>0.05); the survival rate of 3 years and median survival time in the study group were higher than those in the control group (P<0.05). Conclusion: Neoadjuvant chemotherapy of paclitaxel combined with cisplatin can significantly reduce the rate of lymph node metastasis in patients with advanced cervical cancer before operation and reduce the range of lesions, which can improve the clinical effects and help to improve the long-term of survival rate.
|
|
|
|
|
|
[1] 刘少晓,程晓燕,郑红枫,等.紫杉醇联合顺铂新辅助治疗局部晚期宫颈癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(6):432~434.
[2] Thaker PH, Salani R, Brady WE, et al. A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)[J]. Ann Oncol,2017,28(3):505~511.
[3] 覃小敏,李琳,黄艳丽,等.中老年宫颈癌患者预后相关影响因素的分析[J].癌症进展,2015,13(3):346~349.
[4] Wang HY, Yao ZH, Tang H, et al. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma[J]. Oncotarget,2017,8(5):7540~7547.
[5] 王婉,胡倩倩,张伟,等.伊立替康联合顺铂与紫杉醇联合顺铂治疗宫颈癌的临床疗效分析[J].中国妇幼健康研究,2017,28(01):84~87.
[6] Asano H, Todo Y, Watari H. Adjuvant chemotherapy for early-stage cervical cancer[J]. Chin Cancer Res,2016,28(2):228~234.
[7] 万晓丽,罗晓,夏秀英,等.局部晚期宫颈癌术前新辅助化疗疗效观察[J].临床军医杂志,2016,44(10):1066~1069.
[8] Kleinberg LR, Catalano PJ, Forastiere AA, et al. Eastern cooperative oncology group and american college of radiology imaging network randomized phase 2 trial of neoadjuvant preoperative paclitaxel/cisplatin/radiation therapy (RT) or irinotecan/cisplatin/RT in esophageal adenocarcinoma: long-term outcome and implications for trial design[J]. Int Radiat Oncol Biol Phys,2016,94(4):738~746.
[9] Tsuda N, Watari H, Ushijima K. Chemotherapy and molecular targeting therapy for recurrent cervical cancer[J]. Chin Cancer Res,2016,28(2):241~253.
[10] 徐丽伟,张梦真.宫颈癌和宫颈上皮内瘤变组织中成纤维活化蛋白α的表达[J].郑州大学学报:医学版,2015,50(3):375~377.
[11] Elias ST, Borges GA, Rego DF, et al. Combined paclitaxel, cisplatin and fluorouracil therapy enhances ionizing radiation effects, inhibits migration and induces G0/G1 cell cycle arrest and apoptosis in oral carcinoma cell lines[J]. Oncol Lett, 2015,10(3):1721~1727.
[12] Zhao H, Li L, Su H, et al. Concurrent paclitaxel/cisplatin chemoradiotherapy with or without consolidation chemotherapy in high-risk early-stage cervical cancer patients following radical hysterectomy: preliminary results of a phase III randomized study[J]. Oncotarget,2016,7(43):70969~70978. |
|
|
|
2019, Vol. 25 
